Pneumococcal 15-Valent Conjugate Vaccine Approved for Pediatric Use
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.
NVX-CoV2373 is engineered from the genetic sequence of SARS-CoV-2 using the Company’s recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein.
Priorix is administered as a 2-dose series (each dose is approximately 0.5mL) via subcutaneous injection.
Dr Robert Popovian discusses access to immunization services among adults in low-income communities and efforts to expand pharmacists’ authority to administer vaccines to increase vaccination rates for this vulnerable population.
In this interview, Paritosh Prasad, MD, provides insight into the recent outbreak of monkeypox.
The Pfizer-BioNTech COVID-19 vaccine can be administered as a single booster dose to individuals 5 to 11 years of age at least 5 months after completion of the primary series.
Researchers assessed the efficacy of an adjuvanted enterovirus 71 (EV71) vaccine for the prevention of EV71-associated infections among infants and children.
The RSVpreF vaccine candidate consists of 2 prefusion F proteins selected to optimize protection against RSV A and B.
The KidCOVE study is currently evaluating the immunogenicity, safety, and tolerability of the mRNA-1273 vaccine in healthy children.